Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM HRD Study

Phase 1 Clinical Trial ◽

Phase 1 Clinical Trial of Elamipretide in Dry Age-Related Macular Degeneration and Noncentral Geographic Atrophy: ReCLAIM NCGA Study

Ophthalmology Science ◽

10.1016/j.xops.2021.100086 ◽

2021 ◽

pp. 100086

Author(s):

Priyatham S. Mettu ◽

Michael J. Allingham ◽

Scott W. Cousins

Keyword(s):

Clinical Trial ◽

Macular Degeneration ◽

Phase 1 ◽

Geographic Atrophy ◽

Phase 1 Clinical Trial ◽

Faculty Opinions recommendation of Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725825178.793530516 ◽

2017 ◽

Author(s):

Michael Singer

Keyword(s):

Clinical Trial ◽

Gene Therapy ◽

Macular Degeneration ◽

Phase 1 ◽

Randomised Clinical Trial ◽

Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial

The Lancet ◽

10.1016/s0140-6736(15)00345-1 ◽

2015 ◽

Vol 386 (10011) ◽

pp. 2395-2403 ◽

Cited By ~ 86

Author(s):

Elizabeth P Rakoczy ◽

Chooi-May Lai ◽

Aaron L Magno ◽

Matthew E Wikstrom ◽

Martyn A French ◽

...

Keyword(s):

Clinical Trial ◽

Gene Therapy ◽

Macular Degeneration ◽

Phase 1 ◽

Randomised Clinical Trial ◽

Health-Related Quality of Life in Patients with Moderate to Advanced Dry Age-Related Macular Degeneration: Results from a Phase 1/2a Clinical Trial of Cnto 2476

Value in Health ◽

10.1016/j.jval.2016.03.1861 ◽

2016 ◽

Vol 19 (3) ◽

pp. A127 ◽

Cited By ~ 1

Author(s):

RF Pierson ◽

S Orr ◽

J Bogert ◽

T Malone ◽

RD Crosby ◽

...

Keyword(s):

Quality Of Life ◽

Clinical Trial ◽

Macular Degeneration ◽

Phase 1 ◽

Health Related Quality ◽

Age Related ◽

Related Quality ◽

Health Related

One-Year Follow-Up in a Phase 1/2a Clinical Trial of an Allogeneic RPE Cell Bioengineered Implant for Advanced Dry Age-Related Macular Degeneration

Translational Vision Science & Technology ◽

10.1167/tvst.10.10.13 ◽

2021 ◽

Vol 10 (10) ◽

pp. 13

Author(s):

Amir H. Kashani ◽

Jane S. Lebkowski ◽

Firas M. Rahhal ◽

Robert L. Avery ◽

Hani Salehi-Had ◽

...

Keyword(s):

Clinical Trial ◽

Macular Degeneration ◽

Phase 1 ◽

Age Related ◽

One Year

Faculty of 1000 evaluation for Improving function in age-related macular degeneration: a randomized clinical trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718007696.793478654 ◽

2013 ◽

Author(s):

David Boyer

Keyword(s):

Clinical Trial ◽

Macular Degeneration ◽

Faculty Opinions recommendation of Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718007638.793493580 ◽

2014 ◽

Author(s):

Michael Singer

Keyword(s):

Clinical Trial ◽

Fatty Acids ◽

Macular Degeneration ◽

Eye Disease ◽

Omega 3 Fatty Acids ◽

Omega 3 ◽

Age Related ◽

Disease Study

Faculty Opinions recommendation of Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718007638.793477261 ◽

2013 ◽

Author(s):

Karl Csaky ◽

Debbie Chong

Keyword(s):

Clinical Trial ◽

Fatty Acids ◽

Macular Degeneration ◽

Eye Disease ◽

Omega 3 Fatty Acids ◽

Omega 3 ◽

Age Related ◽

Disease Study

A Traditional Chinese Patent Medicine ZQMT for Neovascular Age- Related Macular Degeneration: A Multicenter Randomized Clinical Trial

Current Molecular Medicine ◽

10.2174/1566524019666190107155311 ◽

2019 ◽

Vol 18 (9) ◽

pp. 622-629 ◽

Cited By ~ 2

Author(s):

M. Jin ◽

H. Dai ◽

X. Zhang ◽

Y. Wang ◽

M. Han ◽

...

Keyword(s):

Clinical Trial ◽

Macular Degeneration ◽

Chinese Patent Medicine ◽

Age Related ◽

Chinese Patent ◽

Traditional Chinese Patent Medicine ◽

Patent Medicine

Re: Campochiaro et al.: The Port Delivery System with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 Ladder clinical trial (Ophthalmology. 2019;126:1141-1154)

Ophthalmology ◽

10.1016/j.ophtha.2019.06.019 ◽

2019 ◽

Vol 126 (11) ◽

pp. e87-e88 ◽

Cited By ~ 1

Author(s):

Ashish Sharma ◽

Nilesh Kumar ◽

Baruch D. Kuppermann ◽

Bandello Francesco

Keyword(s):

Clinical Trial ◽

Macular Degeneration ◽

Delivery System ◽

Phase 2 ◽

Age Related ◽

Randomized Phase 2